Surgical robotics

Soft-tissue robotics: monopoly to contested oligopoly

Intuitive Surgical's da Vinci held an effective US monopoly in soft-tissue robotic surgery for two decades — 11,395 installed systems as of Q1 2026 (up 12% YoY), an exclusive surgeon-training pipeline, and the industry's only procedure-volume dataset of any meaningful scale. In the five months between December 2025 and April 2026 that monopoly became a contested oligopoly: Medtronic's Hugo cleared the FDA for urology on 3 December 2025 (prostatectomy, nephrectomy, cystectomy — ~230,000 US surgeries per year), Johnson & Johnson submitted Ottava for de novo authorisation on 7 January 2026 and posted positive pivotal data in Roux-en-Y gastric bypass in May 2026, and CMR Surgical's Versius Plus cleared in cholecystectomy on 17 December 2025 and filed a 510(k) to expand into gynecology on 29 April 2026. Three credible challengers cleared or submitted in a single five-month window. The competition is not yet at the high-volume hospital flagship — it is at community hospitals, ambulatory surgical centres, and the procedure-specific long tail (urology, cholecystectomy, gynecology) that Intuitive's pricing has historically left open.

State of the art (2026)

Mid-2026 finds soft-tissue robotics in the first real competitive year of its history. Intuitive Surgical still anchors the category at 11,395 da Vinci systems (Q1 2026, up 12% year-on-year) with da Vinci 5 now the majority of placements, but its 20-year US monopoly has fractured: Medtronic Hugo cleared FDA for urology on 3 December 2025, CMR Surgical Versius Plus cleared for cholecystectomy on 17 December 2025, and Johnson & Johnson submitted Ottava for de novo classification in upper-abdominal general surgery on 7 January 2026, with pivotal gastric-bypass endpoints met by May. Orthopedic robotics runs the opposite way, consolidating around Stryker Mako against trailing Velys and Mazor. The contest is at the long tail – urology, cholecystectomy, gynecology, ASCs – not yet the hospital flagship.

Orthopedic robotics: consolidating around Stryker Mako

While soft-tissue robotics fragments, orthopedic robotics is moving the opposite way. Stryker reported its best-ever Q1 for Mako installations in Q1 2026 with rising international utilisation; Mako 4 supports hip, knee, and spine, and shoulder migrates onto the Mako 4 platform mid-year 2026 (Mako Shoulder is already in limited release on Mako 3). The handheld Mako RPS launched in limited release in February 2026, opening a smaller-footprint lane optimised for ASCs below the arm-based system. Stryker's hardware-plus-implants flywheel (Mako + Triathlon knee + the shoulder system) compounds the way Intuitive's da Vinci-plus-instruments flywheel did in soft-tissue. Medtronic's Mazor and J&J's Velys are in market in orthopedic but neither has scaled. The position-relevant read on each sub-market is the opposite of the other: a thesis on surgical robotics must be split, not aggregated.

Procedure-growth deceleration reads as bottom-tier contestation

Intuitive's Q1 2026 da Vinci procedures grew approximately 16% (combined da Vinci + Ion ~17%), while management raised the full-year 2026 da Vinci procedure-growth guide to 13.5–15.5% from a prior 13–15%. The guide is higher than before but still sits meaningfully below the in-quarter print, implying ~13–15% growth across the remaining three quarters — a real deceleration concentrated in the urology / cholecystectomy / gynecology long tail where Hugo and Versius Plus are most likely to take share first. Intuitive's procedure mix is concurrently shifting upmarket (da Vinci 5 cardiac clearance January 2026, growing share of complex cases), which is the moat compounding at the top while the perimeter narrows at the base. Structurally this resembles what is now playing out in AI silicon: the incumbent retains the highest-value tier and shares the rest with specialists. The Q2 2026 procedure-mix disclosure is the cleanest leading indicator — if deceleration concentrates in urology and cholecystectomy while cardiac and complex cases hold, the bottom-end displacement thesis is confirmed in the income statement.